- ByProactive Investors
- •
N4 Pharma Plc is a United Kingdom-based specialist pharmaceutical company. The Company is focused on developing a silica nanoparticle delivery system, namely Nuvec for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. Nuvec is a non-viral adjuvant delivery system for vaccines and cancer treatments. This nanoparticle, Nuvec, has the potential to help commercialize cancer immunotherapy drugs and improve the effectiveness of viral vaccines. Its Nuvec silica nanoparticles has an irregular (spiky) surface structure, coupled with polyethyleneimine (PEI), that effectively traps and protects nucleic acid, such as messenger ribonucleic acid (mRNA) as it travels to the cells. Its Nuvec generates predominantly a T Helper Cell Type 1 (Th1) response, characterized by an interferon gamma production, which leads to fight intracellular parasites, such as viruses or to kill cancer cells.